Biomanufacturing — the large-scale production of biologic drugs using living cells — is one of the most technically complex and capital-intensive industrial processes in the world. Novo Nordisk's capacity expansion for GLP-1 products — representing over $10 billion in manufacturing investment — is the most visible example of the manufacturing imperative in modern biotechnology. Biosimilar manufacturers must demonstrate biosimilarity to reference products through extensive characterization, comparability studies, and clinical pharmacology data. The contract manufacturing organization landscape for biologics — encompassing Lonza, Samsung Biologics, WuXi Biologics, and others — has expanded dramatically to meet growing demand.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Biomanufacturing Technology
• Cell Culture and Fermentation
• Novo Nordisk GLP-1 Manufacturing Expansion
• Biosimilar Manufacturing Requirements
• CMO Landscape
• Single-Use Bioprocessing
• Continuous Manufacturing
• Supply Chain Resilience
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. Biomanufacturing Technology
4. Cell Culture and Fermentation
5. Novo Nordisk GLP-1 Manufacturing Expansion
6. Biosimilar Manufacturing Requirements
7. CMO Landscape
8. Single-Use Bioprocessing
9. Continuous Manufacturing
10. Supply Chain Resilience
11. Competitive Landscape
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. Biomanufacturing Technology
Table 3. Cell Culture and Fermentation
Table 4. Novo Nordisk GLP-1 Manufacturing Expansion
Table 5. Biosimilar Manufacturing Requirements
Table 6. CMO Landscape
Table 7. Single-Use Bioprocessing
Table 8. Continuous Manufacturing
Table 9. Supply Chain Resilience
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Novo Nordisk
Eli Lilly
Sanofi
AstraZeneca
Pfizer
Roche
Viking Therapeutics
Structure Therapeutics
